Solriamfetol for Binge Eating Disorder

This trial aims to test the effectiveness and tolerability of solriamfetol for treating binge eating disorder (BED). Solriamfetol affects brain chemicals to help control urges to binge eat. Participants will receive either solriamfetol or a placebo (an inactive pill) to compare outcomes. Individuals who have experienced frequent binge eating episodes, at least three times a week for the past week, might be a good fit for this trial.

As a Phase 4 trial, this research seeks to understand how this already FDA-approved and effective treatment can benefit more patients.

The trial requires that you stop taking any psychotropic medications (medications affecting mood, perception, or behavior) at least four weeks before starting the study. This includes antidepressants, antipsychotics, mood stabilizers, and psychostimulants. If you are on any medications that might interact with the study drug, like warfarin or anticonvulsants, you may also need to stop those.

Research has shown that solriamfetol is generally safe and well-tolerated in people. In previous studies, the observed side effects were expected and manageable. Solriamfetol has already received approval for other uses, providing some reassurance about its safety. While no treatment is without risk, current evidence suggests that solriamfetol is a relatively safe option for those considering joining a clinical trial for binge eating disorder.¹²³⁴⁵

Unlike the standard treatments for binge eating disorder, which typically include options like cognitive behavioral therapy and medications such as selective serotonin reuptake inhibitors (SSRIs), solriamfetol offers a novel approach by acting as a dopamine and norepinephrine reuptake inhibitor. This unique mechanism of action potentially enhances focus and energy levels, which could help reduce binge-eating episodes. Researchers are excited about solriamfetol because it might provide quicker behavioral improvements compared to other medications, offering a promising alternative for those who don't respond well to existing treatments.

This trial will evaluate the effectiveness of solriamfetol for binge eating disorder (BED). Research has shown that solriamfetol, a type of medication, is effective for certain conditions. It is approved for treating excessive daytime sleepiness in people with narcolepsy and sleep apnea. Although direct evidence for its use in BED is limited, its mechanism suggests it might help reduce binge eating episodes. Solriamfetol increases levels of certain brain chemicals, dopamine and norepinephrine, which can influence mood and impulse control. Early signs are promising, but more research is needed to confirm its effectiveness for BED specifically. Participants in this trial will receive either solriamfetol or a placebo to assess its potential benefits for BED.¹³⁴⁵⁶